Skip to content

Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers

Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers in Postmenopausal Women.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06042673
Enrollment
15
Registered
2023-09-18
Start date
2023-07-06
Completion date
2024-07-28
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Women

Brief summary

Dietary fat plays a crucial role as a modifiable risk factor influencing both non-fasting lipaemia and vascular reactivity. Notably, the intake of dietary saturated fatty acids (SFAs) has been associated with adverse effects on blood lipid profiles, whereas increased consumption of unsaturated fatty acids (UFAs) has shown potential to improve lipid health. Pomegranate seed oil (PSO) stands out due to its high content of conjugated α-linolenic acids (CLnAs). However, research comparing the impact of these fatty acids on postprandial vascular function, particularly in postmenopausal women, remains limited. A cross-over, single-blind, randomised acute postprandial study will be conducted in 15 healthy postmenopausal women. Participants will be assigned to consume the test meals either a placebo (50 g of mixed fat; 4:0.5:0.5 palm oil: rapeseed oil: safflower oil) or PSO (40 g of mixed fat and 10g of PSO) in random order on 2 separate occasions, with 4-6 weeks between each study visit. The anthropometric, blood pressure, and arterial stiffness, will be taken for each study visit. Blood samples will be collected for the measurement of fasting lipids, glucose, insulin, inflammatory markers, and whole blood culture. The findings from this study will contribute to the evidence base on how consuming meals rich in PSO influence the level of blood lipids as well as other biomarkers for cardiovascular disease.

Interventions

DIETARY_SUPPLEMENTPomegranate seed oil

10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast

DIETARY_SUPPLEMENTMixed vegetable oil

50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast

Sponsors

University of Reading
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Postmenopausal women who have been postmenopausal for at least 12 months. * Aged 65 and under years * Serum TAG \< 2.3 mmol/l * Body mass index (BMI) between 18-35 kg/m2 * Fasting total cholesterol \< 7.5 mmol/l * Fasting glucose concentration \<7 mmol/L

Exclusion criteria

* Smokers * Medical history of myocardial infarction or stroke in the past 12 months * Diabetes (defined as fasting glucose \> 7.0 mmol/l) or other endocrine disorders * Kidney, liver, pancreas or gastrointestinal disorder * Hypertension (blood pressure \> 140/90 mmHg), cancer, medication for hyperlipidaemia (e.g. statins), hypertension or, inflammation * Anaemia (\<115 g/L haemoglobin) * Taking any dietary supplements known to influence lipids/gut microbiota (e.g. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics) * Drinking in excess of 14 units of alcohol per week * Planning on a weight-reducing regime * Parallel participation in another dietary intervention study * Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in postprandial triacylglycerolAcute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutesTriacylglycerol

Secondary

MeasureTime frameDescription
Fasting blood lipidsAcute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutesTotal cholesterol, high density lipoprotein cholesterol
Change from baseline in postprandial insulinAcute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutesInsulin
Change from baseline in postprandial endothelial activationAcute study: taken at 0 (baseline),180, 300 and 420 minutesE-selectin, P-selectin, vascular cell adhesion molecule 1, intercellular adhesion molecule-1
Change from baseline in postprandial blood pressureAcute study: taken at 0 (baseline), 120, 240, 360 and 480 minutesSystolic and diastolic blood pressure Systolic and diastolic blood pressure Systolic and diastolic blood pressure Systolic and diastolic blood pressure
Change from baseline endothelial microvascular functionAcute study: taken at 0 (baseline),180, 300 and 420 minutesLaser Doppler imaging (LDI) with iontophoresis

Countries

United Kingdom

Contacts

Primary ContactJeremy Spencer, BSc, PhD
j.p.e.spencer@reading.ac.uk+44(0)1183788724

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026